Exact Sciences is building a brand it hopes will become intimately linked with cancer testing. Once it does that, it will not need to spend as much on sales and marketing to attract customers.

Exact Sciences Corp., a biotechnology company that has grown rapidly since moving to Madison less than a decade ago, broke ground this week on a new headquarters building to accommodate that growth.

Exact Sciences Q3 Earnings: Profitability Goal Execution Momentum Building Into 2023. Nov. 09, 2022 10:45 PM ET Exact Sciences Corporation (EXAS) Stock EXAS 4 Comments 5 Likes. Bashar Issa.

Exact Sciences, the Madison-based biosciences company that makes and markets a test to detect the second-deadliest type of cancer in the United States, says it is adding laboratory space in Madison.

Exact Sciences is building a cup without handle with a 72.83 buy point.See if it can clear the breakout price in volume at least 40% above average. Exact Sciences reported 0% EPS growth in its ...

Diagnostic company Exact Sciences Corporation (NASDAQ:EXAS) announced in Q4 CY2024, with sales up 10.3% year on year to $713.4 million. The company expects the full year’s revenue to be around ...

EXAS Price Action: Exact Sciences has a 52-week high of $84.46 and a 52-week low of $29.27. The stock was up 16.1% at $54.72 at time of publication, according to Benzinga Pro . Photo: courtesy of ...

Exact Sciences is building a second laboratory facility in Madison, Wis., to meet growing demand for the company's Cologuard test. Here's what you should know: 1. The new laboratory will add 250-plus ...

No matter how you look at it, Exact Sciences (NASDAQ: EXAS) has been a big winner. Shares of the company best known for its Cologuard colorectal cancer screening test have skyrocketed nearly 6,000 ...

Madison-based cancer diagnostics company Exact Sciences Corp. said Monday it plans to acquire Redwood City, California-based Genomic Health in a $2.8 billion cash-and-stock deal.